FINWIRES · TerminalLIVE
FINWIRES

研究快讯:CFRA维持对Hexcel公司股票的“持有”评级

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将Hexcel未来12个月的目标价上调7美元至97美元,相当于2027年每股收益预期值的31.7倍,高于HXL过去三年的平均预期市盈率30.5倍和同行平均市盈率36.5倍。我们将2026年每股收益预期上调0.08美元至2.36美元,2027年每股收益预期上调0.10美元至3.06美元。Hexcel第一季度的业绩凸显了其稳健的基本面,这得益于商业航空航天业的持续复苏。受空客A350和A320以及波音787和737 MAX等关键项目产量提升的推动,商用航空航天销售额同比增长18.8%,预计2026年A350的产量将达到约80架。销量增长带来了显著的运营杠杆效应,毛利率提升至26.9%,调整后营业收入增长49%,这得益于公司对现有产能的充分利用。尽管由于之前的资产剥离,国防、航天及其他业务的销售额有所下降,但预计2026年下半年导弹相关需求将加速增长。作为领先的复合材料供应商,Hexcel凭借其在提升飞机燃油效率方面日益增长的复合材料应用,占据了有利地位。

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP